Bristol
Beyond's analysis on Bristol
Recent news mentioning Bristol
- — Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
- — Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
- — Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
- — Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
- — Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth
- — Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK
- — Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
- — Turn Bristol-Myers Squibb into an Income Machine with This Options Play
- — Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
- — Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
- — Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
- — AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?